Mixture-of-Recursions (MoR) is a new AI architecture that promises to cut LLM inference costs and memory use without ...

As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, ...

RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.

It will also be eligible to receive low single-digit royalties on all future net sales by Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) and likewise earn payments in the event of the latter’s sale of ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion Pharmaceuticals (NASDAQ: RXRX) surged by more than 12% by 11 a.m. ET today. The move is ...

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...

Rallybio (NASDAQ:RLYB) stock soars 114% after agreeing to sell its stake in a rare bone disorder asset, extending cash runway to mid-2027. Read more here.